Undisclosed COPD Program
Chronic Obstructive Pulmonary Disease (likely targeting inflammation/exacerbations)
Pre-clinicalActive
Key Facts
Indication
Chronic Obstructive Pulmonary Disease (likely targeting inflammation/exacerbations)
Phase
Pre-clinical
Status
Active
Company
About Pulmobiotics
Pulmobiotics is an early-stage biotech developing a novel platform of engineered bacteria for direct pulmonary delivery. Its technology aims to reprogram the lung microbiome to combat infections, reduce inflammation, and address the underlying pathology of chronic respiratory diseases. The company is likely in a pre-clinical or research stage, targeting significant unmet medical needs in CF and COPD with a potentially disruptive therapeutic modality. As a private, pre-revenue entity, its success hinges on platform validation, securing further funding, and navigating the complex regulatory pathway for live biotherapeutics.
View full company profile